Audrey Andrews

Authored Items
Suboptimal Dosing of Filgrastim Is Acceptable for Treatment of Chemotherapy-Induced Neutropenia
Audrey Andrews
TOP - August 2018, Vol 11, No 2 in Side-Effects Management
Project Aims to Prevent Future Infusion-Related Reactions
Audrey Andrews
TOP - May 2017, Vol 10, No 2 in NCCN News, NCCN
Noncompliance with Granulocyte Colony-Stimulating Factor Guidelines Has Consequences
Audrey Andrews
TOP - May 2017, Vol 10, No 2 in NCCN News, NCCN
Pharmacy-Led Intervention Improved Tyrosine Kinase Inhibitor Adherence and Monitoring
Audrey Andrews
TOP - May 2017, Vol 10, No 2 in NCCN News, NCCN
New Survey Reveals How Pharmacies Manage Verification Processes
Audrey Andrews
TOP - November 2016, Vol 9, No 4 in Best Practices
Dose Modifications of Lenalidomide Lead to Good Outcomes in Myelodysplastic Syndrome
Audrey Andrews
TOP - November 2016, Vol 9, No 4 in Hematologic Cancers
Managing Dermatologic Toxicities
Audrey Andrews
TOP November 2015 Vol 8 No 4 in Conference Correspondent
Managing Dermatologic Toxicities
Audrey Andrews
Web Exclusives in Conference Correspondent
Peripheral Arterial Disease Seen With Nilotinib
Audrey Andrews
TOP - February 2013 VOL 6, NO 1 in Supportive Care
Crizotinib Is Just the Beginning
Audrey Andrews
TOP - December 2012 VOL 5, NO 8
Exemestane: A Promising New Option for Primary Prevention of Breast Cancer
Audrey Andrews
Online First in Conference Correspondent
Bevacizumab in Ovarian Cancer: More Support for Maintenance
Audrey Andrews
Online First in Conference Correspondent
Novel Agents Improve Survival in Metastatic Melanoma
Audrey Andrews
Online First in Conference Correspondent
PARP Inhibitor Prolongs Progression-Free Survival in Ovarian Cancer
Audrey Andrews
Online First in Conference Correspondent
NCCN Helps Guide Optimal Use of Myeloid Growth Factors for Prevention of Neutropenia
Audrey Andrews
Online First in Supportive Care
Last modified: December 11, 2015